Skip to main content
Fig. 27 | Cancer Nanotechnology

Fig. 27

From: Evaluation of the anticancer potential of CD44 targeted vincristine nanoformulation in prostate cancer xenograft model: a multi-dynamic approach for advanced pharmacokinetic evaluation

Fig. 27

Pure VC treatment groups showed severe toxicities, including significant neurotoxicity (C1), hepatotoxicity (C4) and renal toxicity (C3), with comparatively lesser toxicity seen in cardiac tissues (C2) and lung tissues (C5). However, VC-loaded TCs-HA NFs treatment groups showed reduced off-target toxicities (D1 to D5) with cytotoxic anti-tumour effects and a possibility of slower angiogenesis; n = 10, mean + SD, p ≤ 0.05. Images were taken at 10 × and 40 ×

Back to article page

Cancer Nanotechnology

ISSN: 1868-6966

Contact us